Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 May;12(5):261.
doi: 10.1038/nrcardio.2015.51. Epub 2015 Mar 31.

Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab

Karina Huynh
Comment

Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab

Karina Huynh. Nat Rev Cardiol. 2015 May.
No abstract available

PubMed Disclaimer

Comment on

  • Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
    Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Robinson JG, et al. N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773378 Clinical Trial.
  • Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
    Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Sabatine MS, et al. N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773607 Clinical Trial.

References

    1. N Engl J Med. 2015 Apr 16;372(16):1489-99 - PubMed
    1. N Engl J Med. 2015 Apr 16;372(16):1500-9 - PubMed

MeSH terms

Substances